Vyome Biosciences has closed a US$14 million Series-C funding round, led by New York-based Perceptive Advisors and Boston-based Romulus Capital.
The specialty bio-pharmaceutical firm will employ the cash primarily to further advance research and development of a ground-breaking acne treatment aimed at tackling antibiotic-resistant acne. The treatment is at the clinical trial stage after receiving Investigational New Drug approval from the US FDA.
“The support from leading global and leading life investors and the continued support from our largest existing shareholders validates our company’s strategy, science and development programs. We will utilize these funds predominantly to advance the clinical development of our lead prduct, VB 1953, while continuing to develop other proprietary products in our pipeline,” said Venkateswarlu Nelabhotla, CEO.